GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Collaborations
  • Careers
  • Contact
  • Menu Menu

News Archive

GigaGen Announces Publication in the Peer-Reviewed Journal mAbs

10/20/2020/by jkeller

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]

Read more

GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050

09/09/2020/by jkeller

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]

Read more

GEN: Drug Targets Identified More Discerningly

09/01/2020/by jkeller

“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]

Read more

BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

08/12/2020/by jkeller

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]

Read more

KPIX-TV (CBS): Bay Area Biotech Company Takes New Approach in COVID-19 Treatment

08/10/2020/by jkeller

A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.

Read more

Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests

08/10/2020/by jkeller

Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]

Read more

BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

08/10/2020/by jkeller

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]

Read more

GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

08/10/2020/by jkeller

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]

Read more

GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

07/29/2020/by jkeller

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.

Read more

BioPharm International: Plasma-Based Antibody Therapies Battle Against COVID-19

06/01/2020/by jkeller

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.

Read more

San Francisco Business Times: Biotech adapts to new working conditions in the age of Covid-19

05/26/2020/by jkeller

Read the full story.

Read more

Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses

05/04/2020/by jkeller

David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.

Read more

Nature Biotechnology: Convalescent serum lines up as first-choice treatment for coronavirus

05/01/2020/by jkeller

Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]

Read more

TIME: Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About

04/14/2020/by jkeller

It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]

Read more

WGNO-TV (ABC): Coronavirus Survivors Needed: New Orleans Doctor is collecting blood samples from survivors to make treatment

04/13/2020/by jkeller

Watch the tv news report.

Read more

GEN: Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

04/13/2020/by jkeller

Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.

Read more

The Lens: Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment

04/08/2020/by jkeller

Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]

Read more

Chemical & Engineering News: Searching for a coronavirus cure in the blood: Scientists look to convalescent plasma, hyperimmune therapy, and monoclonal antibodies to treat COVID-19

04/07/2020/by jkeller

Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]

Read more

Pharmaceutical Technology: GigaGen works on recombinant polyclonal antibody against Covid-19

03/31/2020/by jkeller

Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.

Read more

San Francisco Business Times: Peninsula biotech readies attack on COVID-19 — all it needs now is more cash and recovered patients’ blood

03/30/2020/by jkeller

The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.

Read more
Page 1 of 41234

Latest Tweets

GigaGenFollow

GigaGen
GigaGen@gigageninc·
4 Mar

Our final spotlight goes to Kacy Stadtmiller! Her strong experience in #cancer & #immunology research has been fundamental in advancing our pipeline, including enhancing our ability to sort #antibody libraries to identify unique therapeutic targets. #InternationalWomensDay2021

Reply on Twitter 1367475341124636676Retweet on Twitter 13674753411246366762Like on Twitter 13674753411246366761Twitter 1367475341124636676
GigaGen@gigageninc·
3 Mar

Next up is chemical engineer, Ellen Wagner! She leads several innovative projects as part of the technology development team at GigaGen, and directs the protein purification group that developed the unique process for our #COVID19 drug in development. #InternationalWomensDay2021

Reply on Twitter 1367112750099550213Retweet on Twitter 1367112750099550213Like on Twitter 13671127500995502131Twitter 1367112750099550213
GigaGen@gigageninc·
2 Mar

Meet Yoong Wearn Lim! As a computational biologist specialized in #ImmunoOncology target discovery, antibody repertoire analysis & #SingleCell genomics, her skills were fundamental to help build our #oncology target discovery platform, Magnify. #InternationalWomensDay2021

Reply on Twitter 1366750382819602438Retweet on Twitter 13667503828196024381Like on Twitter 13667503828196024383Twitter 1366750382819602438
GigaGen@gigageninc·
25 Feb

March 8th is #InternationalWomensDay2021! Leading up to it, we will be highlighting a couple of the wonderful women scientists on our team at GigaGen and some of the accomplishments they’ve made throughout their careers. Check back for more information.

Reply on Twitter 1364939101934411778Retweet on Twitter 1364939101934411778Like on Twitter 1364939101934411778Twitter 1364939101934411778
GigaGen@gigageninc·
20 Jan

Today’s #EmployeeHighlight goes to our VP of #oncology, Dr. Erica Stone (@StoneEL2)! Dr. Stone’s deep expertise in cancer #immunology research has driven the outstanding progress in our immuno-oncology research & discovery program. Learn more: https://bit.ly/375iuJ4

Reply on Twitter 1351892687612497920Retweet on Twitter 1351892687612497920Like on Twitter 13518926876124979201Twitter 1351892687612497920
© Copyright 2020 GigaGen. All Rights Reserved.
  • Twitter
  • LinkedIn
Scroll to top